Key Points
- Melissa Starovasnik sold 500 shares on April 27 at an average price of $61.83 under a Rule 10b5-1 plan, reducing her stake by 1.94% to 25,222 shares (about $1.56M).
- Twist missed quarterly EPS expectations with ($0.50) versus ($0.48) estimates, though revenue grew 16.9% year-over-year to $103.7M; the company remains unprofitable with negative margins and a projected full-year EPS of -1.86.
- Analyst coverage is mixed but leans positive—seven Buys vs. two Sells—with several firms raising targets (some to $55) and a MarketBeat average rating of "Moderate Buy" and average target of $47.13.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) Director Melissa Starovasnik sold 500 shares of the business's stock in a transaction on Monday, April 27th. The stock was sold at an average price of $61.83, for a total transaction of $30,915.00. Following the transaction, the director directly owned 25,222 shares of the company's stock, valued at approximately $1,559,476.26. This represents a 1.94% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Twist Bioscience Stock Down 4.1%
Shares of TWST opened at $56.70 on Thursday. The company has a 50-day simple moving average of $50.35 and a 200-day simple moving average of $40.79. The firm has a market capitalization of $3.48 billion, a P/E ratio of -44.30 and a beta of 2.20. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $66.06.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. The firm's quarterly revenue was up 16.9% compared to the same quarter last year. On average, equities research analysts expect that Twist Bioscience Corporation will post -1.86 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several research firms recently issued reports on TWST. Barclays increased their price target on shares of Twist Bioscience from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research report on Friday, March 27th. Guggenheim increased their price target on shares of Twist Bioscience from $50.00 to $55.00 and gave the stock a "buy" rating in a research report on Monday, March 30th. TD Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Finally, Evercore increased their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $47.13.
Read Our Latest Stock Analysis on TWST
Institutional Trading of Twist Bioscience
Hedge funds have recently modified their holdings of the company. Campbell & CO Investment Adviser LLC grew its stake in shares of Twist Bioscience by 227.6% during the third quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company's stock valued at $1,328,000 after purchasing an additional 32,792 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of Twist Bioscience by 14.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company's stock valued at $41,171,000 after acquiring an additional 184,726 shares during the last quarter. Baillie Gifford & Co. raised its position in shares of Twist Bioscience by 62.8% during the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company's stock valued at $35,533,000 after acquiring an additional 487,052 shares during the last quarter. EdgePoint Investment Group Inc. raised its position in shares of Twist Bioscience by 71.1% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company's stock valued at $114,876,000 after acquiring an additional 1,696,377 shares during the last quarter. Finally, First Light Asset Management LLC raised its position in shares of Twist Bioscience by 26.4% during the 3rd quarter. First Light Asset Management LLC now owns 1,194,883 shares of the company's stock valued at $33,624,000 after acquiring an additional 249,850 shares during the last quarter.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
